Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

The purpose of this study is to assess the safety, tolerability and preliminary efficacy of HRS-5041 in men with progressive metastatic castration resistant prostate cancer. The objective of this study was to determine the dose-limiting toxicity, maximum tolerance and recommended dose of HRS-5041 in phase II study.

Trial Details

NCT ID
NCT05942001
Phase
PHASE1
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • HRS-5041
  • Docetaxel injection
  • Abiraterone acetate tablets
  • Prednisone Acetate Tablets
  • Enzalutamide Soft Capsules
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Able and willing to provide a written informed consent.
  • Age 18-80 years old, gender unlimited.
  • The physical status score of the Eastern Tumor Cooperative Group (ECOG) was 0 \~ 1.
  • Predicted survival ≥12 weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →